. 2019 Apr 8;8(2):185–198. doi: 10.1007/s40121-019-0243-4

Table 3.

Comparison of cumulative fraction of response against each pathogen for each drug dosing regimen at each PK/PD target

Drug	PK/PD target	CFR (%)
		Staphylococcus aureus			Streptococcus pneumoniae	Haemophilus influenzae
		MSSA	MRSA	All S. aureus	Streptococcus pneumoniae	Haemophilus influenzae
Levofloxacin	fAUC/MIC > 33.7, 500 mg dose	95.10	52.57	75.14	57.41	N/A
	fAUC/MIC > 33.7, 750 mg dose	96.26	53.74	76.31	82.02	N/A
	fAUC/MIC > 100, 500 mg dose	N/A	N/A	N/A	N/A	97.70
	fAUC/MIC > 100, 750 mg dose	N/A	N/A	N/A	N/A	97.98
Ceftriaxone	20% fT > MICIC	86.20	2.33^a	37.06	99.05	100
	50% fT > MIC	61.42	1.11^a	26.08	97.40	99.7
	80% fT > MIC	41.83	0.61^a	17.68	94.53	99.78
Ceftaroline	Bacteriostasis 26.8% fT > MIC	100	99.82	99.89	N/A	N/A
	1-log reduction 30.7% fT > MIC	100	99.68	99.81	N/A	N/A
	2-log reduction 34.7% fT > MIC	100	99.38	99.64	N/A	N/A
	Bacteriostasis 35% fT > MIC	N/A	N/A	N/A	99.96	N/A
	1-log reduction 44% fT > MIC	N/A	N/A	N/A	99.95	N/A
	2-log reduction 51% fT > MIC	N/A	N/A	N/A	99.93	N/A
	Bacteriostasis 48.5% fT > MIC	N/A	N/A	N/A	N/A	99.97
	1-log reduction 73% fT > MIC	N/A	N/A	N/A	N/A	99.91

AUC area under the curve, CFR cumulative fraction of response, fAUC/MIC free area under the concentration–time curve:MIC ratio, fT > MIC percentage of time that free concentration is above the MIC, MIC minimum inhibitory concentration, MRSA methicillin-resistant S. aureus, MSSA methicillin-sensitive S. aureus, N/A not applicable, PK/PD pharmacokinetic/pharmacodynamic

^aCeftriaxone is not active against MRSA